51 related articles for article (PubMed ID: 8857232)
21. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
Hofmann WK; Seipelt G; Langenhan S; Reutzel R; Schott D; Schoeffski O; Illiger HJ; Hartmann F; Balleisen L; Franke A; Fiedler F; Huber C; Rasche H; Bergmann L; Ganser A; Pott C; Pasold R; Rudolph C; Ottmann OG; Gökbuget N; Hoelzer D
Ann Hematol; 2002 Oct; 81(10):570-4. PubMed ID: 12424538
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
23. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
24. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
25. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)--results of a prospective randomised monocentre study.
Bönig H; Silbermann S; Weller S; Kirschke R; Körholz D; Janssen G; Göbel U; Nürnberger W
Bone Marrow Transplant; 2001 Aug; 28(3):259-64. PubMed ID: 11535993
[TBL] [Abstract][Full Text] [Related]
26. [Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].
Lu DP; Liu KY; Guo NL; Shi YK; He XH; Lou FD; Da WM; Zhang BL; Wang LX; Ke XY
Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):68-70. PubMed ID: 12697098
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy dose-escalation with hemopoietic growth factor support in ovarian cancer.
Willemse PH; Boonstra H; de Vries EG
Semin Oncol; 1994 Dec; 21(6 Suppl 16):44-50. PubMed ID: 7528450
[No Abstract] [Full Text] [Related]
28. [Effect of rG-CSF on the morphology and function of neutrophils in ovarian cancer chemotherapy].
Hoshino T; Suzuki Y; Adachi T; Okabe K; Takayama M
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Nov; 45(11):1320-4. PubMed ID: 7505028
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy and granulocyte colony-stimulating factor in ovarian cancer.
Ochiai K; Terashima Y
Semin Oncol; 1994 Feb; 21(1 Suppl 1):23-8. PubMed ID: 7512275
[No Abstract] [Full Text] [Related]
30. [Clinical trial of CSF-HU (colony-stimulating factor derived from human urine: P-100) on granulocytopenia induced by anticancer therapy in urogenital cancer patients].
Matsumoto K; Kakizoe T; Nakagami Y; Rin S; Ito H; Koyanagi T; Sakashita S; Nagayama T; Miyauchi T; Toyoshima A
Hinyokika Kiyo; 1987 Jun; 33(6):972-82. PubMed ID: 3499770
[TBL] [Abstract][Full Text] [Related]
31. Restorative effect of muroctasin on leukopenia caused by anticancer chemotherapy in lung cancer. Comparative study by envelope method.
Fukuoka M; Takada M; Takifuji N; Sakai N; Ryu S; Masuda N; Matsui K; Negoro S; Kusunoki Y; Tubura E
Arzneimittelforschung; 1989 Jan; 39(1):90-3. PubMed ID: 2719748
[TBL] [Abstract][Full Text] [Related]
32. Timing of G-CSF administration based on the circadian rhythm in patients with ovarian cancer.
Sato S; Kigawa J; Irie T; Itamochi H; Kanamori Y; Kamazawa S; Akeshima R; Terakawa N
Am J Clin Oncol; 2002 Jun; 25(3):289-90. PubMed ID: 12040291
[TBL] [Abstract][Full Text] [Related]
33. [A case report: patient with advanced ovarial tumour and supporting care].
Brančíková D; Ostřížková L; Protivánková M; Bednařík O; Mechl Z
Klin Onkol; 2012; 25(6):464-7. PubMed ID: 23301650
[TBL] [Abstract][Full Text] [Related]
34. [Infection in genitourinary cancer patients during cancer chemotherapy].
Ito Y; Komeda H; Saitoh A; Deguchi T; Ban Y; Kawada Y
Hinyokika Kiyo; 1994 Mar; 40(3):221-4. PubMed ID: 8178738
[TBL] [Abstract][Full Text] [Related]
35. [Large number of immature granulocytes in ascites caused by granulocyte colony-stimulating factor after chemotherapy for ovarian cancer: report of a case].
Guo XL; Lu J; Qiao XY; Xi YF
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):504-506. PubMed ID: 38678338
[TBL] [Abstract][Full Text] [Related]
36. [Studies of delayed hypersensitivity and composition of the population of mononuclear cells in the blood of patients with malignant ovarian neoplasms before and during the treatment].
Markowska J
Ginekol Pol; 1987 May; 58(5):306-13. PubMed ID: 3666526
[No Abstract] [Full Text] [Related]
37. Clinical evaluation of human granulocyte colony-stimulating factor in chemotherapy for ovarian cancer.
Nagai N; Takehara K; Murakami T; Ohama K; Miyaoka S; Fujii T; Matsubayashi S
Hiroshima J Med Sci; 1995 Dec; 44(4):99-103. PubMed ID: 8857232
[TBL] [Abstract][Full Text] [Related]
38. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
39. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
40. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
